A recent study suggests that people who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide may regain lost weight far faster than those who halt traditional lifestyle regimens.
Published data in a major medical journal shows that while obese people frequently drop a large proportion of their body weight while on the medication, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals using these drugs must be informed of the risk of rapid rebound weight gain when the medication is stopped," stated researcher Dr. Susan Jebb.
That rate of regain implies a return to starting mass within about a year and a half.
Analyzing Approaches
The study, which looked at dozens of trials involving thousands of participants, contrasted the outcomes of the injectable medications with older methods.
The team point out that people who shed pounds through lifestyle changes alone usually see a more gradual creep back—perhaps 100 grams monthly—once they finish.
Understanding the Quick Rebound
Doctors propose the mode of action of the injections accounts for the amplified weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which helps regulate appetite.
"Long-term administration of the hormone levels far above than normal could lead to the body to generate a reduced amount of its endogenous hormone, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement results in appetite is no longer kept in check, making excessive eating a significant risk."
A Lifelong Disease?
Health authorities suggest the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Many experts say that, considering the significant potential of relapse, the therapy should be considered long-term.
This view is echoed by pharmaceutical companies, who say that the results "underscore the persistent character of obesity," similar to managing diseases like hypertension.
User Testimonies
Users who have come off the jabs describe a intense resurgence of hunger.
"I experienced a trigger flipping and I was suddenly starving," said a patient.
The struggle is compounded if patients have not established permanent lifestyle or habit modifications during treatment.
Significant Use
Recent estimates show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is more common among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
Ultimately, researchers stress that while GLP-1 drugs are potent tools for weight loss, they are not a magic fix and lasting health benefits hinges on combined behavioural support.
